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In response to injury, mature vascular smooth muscle cells (SMCs) undergo 
dedifferentiation, also known as phenotype modulation or switch. This process is 
characterized by a downregulation or loss of expression of contractile genes and 
concomitant with an increase in cell proliferation, migration, and extracellular matrix 
production, thereby leading to vascular lesion formation. However, the underlying 
molecular mechanism is not fully understood. The objective of my study was to 
determine whether cyclin-dependent kinase 8 (CDK8), a transcription-regulating kinase, 
plays a mediator role in vascular SMC dedifferentiation and lesion formation. Our results 
from immunochemical staining and Western blot revealed that CDK8 expression was 
upregulated in vascular SMCs in mouse injured arteries and human arteries with 
atherosclerosis. In cultured rat aortic SMCs (RASMCs), the dedifferentiated phenotype 
exhibiting the downregulation of SMC contractile genes such as smooth muscle 22 alpha 
(SM22α), calponin-1 (CNN1), and alpha smooth muscle actin (αSMA) as well as 
increased proliferation, migration, and cytokine production was dramatically suppressed 
and reversed into a more differentiated state by CDK8 inactivation via highly selective 
CDK8 inhibitor, Senexin A, and shRNA knockdown approaches. Peri-vascular delivery 
of CDK8 inhibitor, Senexin A attenuated ligation-induced neointima (NI) formation in 
mouse carotid arteries. At the molecular level, we uncovered that CDK8 facilitated the 
activation of AKT to inhibit GSK3β which phosphorylates c-MYC for degradation by
v 
proteasomes, thereby promoting vascular SMC dedifferentiation. In addition, activated 
CDK8 formed signaling complex with AKT thereby activating AKT in vascular SMCs. 
In conclusion, our results demonstrate that CDK8 is a critical mediator of vascular SMC 
dedifferentiation at least partly by facilitating the AKT-mediated inhibition of GSK3β to 
stabilize c-MYC, thereby contributing to NI formation. Targeting CDK8 may be a novel 
therapeutic approach for the treatment of occlusive vascular disease due to the abnormal 
growth of vascular SMCs. 
vi 
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CHAPTER 1 
THE HISTORY OF VASCULAR DISEASE AND CYCLIN-DEPENDENT 
KINASE 8 FUNCTION 
1.1 VASCULAR DISEASE: 
Vascular disease is classified as an abnormality associated with the vascular 
structure and function of blood vessels. There are several types of vascular diseases such 
as atherosclerosis, restenosis, hypertension, and aneurysm. Although their fate differs, 
these vascular diseases share are common pathological process, which are vascular 
remodeling and the development of neointimal formation. This eventually results in the 
occlusion of the blood vessel, which can lead to several complications. Vascular disease 
is the world’s number one killer, accounting for 17.5 million deaths globally.1,2 The exact 
cause of the disease is unknown, however, scientist and clinicians have identified factors 
that can raise the risk for vascular disease. The major risk factors include unhealthy blood 
cholesterol level, high blood pressure, smoking, insulin resistance, diabetes, obesity, and 
physical inactivity. Age and family history have also been found to potentially influence 
the onset of the disease. 
Often, there are no signs or symptoms of vascular disease until the artery is 
severely narrowed or occluded, by which time can cause heart attack or stroke. The signs 
and symptoms vary depending on the artery affected, but can range from weakness, 
paralysis, apnea, unconscious, and overall loss of cognitive function. Doctors diagnose 
atherosclerosis by a physical examination, diagnostic tests, and/or family and medical
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 history. Currently, there is no known cure for vascular disease, however there are a 
number of medications that can be used to slow the progression of the disease. Such 
medications include cholesterol medications, beta-blockers, angiotensin-converting 
enzyme inhibitors, calcium channel blockers, and triamterene/hydrochlorothiazide (water 
pills). In severe cases, the doctor may recommend surgical procedures such as 
angioplasty, stent placement, or bypass surgery. However, these procedures are not a 
permanent solution due to the re-narrowing on the artery, known as restenosis, and often 
require a repeat procedure. Given the inadequacy of current medications and the 
complications involving surgery, an extensive amount of research has been conducted to 
develop new therapies for the treatment of vascular disease. 
 
1.2 CELLULAR MECHANISMS OF VASCULAR DISEASE: 
The structure and cellular composition of blood vessels are consistent throughout 
the vascular system. However, there are certain features in the vasculature that vary and 
reflect distinct functional requirements depending on their location. The basic cellular 
components of a blood vessel consist of endothelial cells (EC), vascular smooth muscle 
cells (VSMC), and extracellular matrix (ECM)—which are comprised of collagen, 
elastin, and proteoglycans. 
The vascular system is organized into three concentric layers: the tunica intima, 
tunica media, and tunica adventitia, and is most distinctive in large vessels such as 
arteries. The tunica intima is the innermost layer and comprised of ECs lining the lumen 
of the vessel (known as the endothelium), a subendothelial layer that consist of 
predominately connective tissue, and the internal elastic lamina, which separates the 
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intima from the media layer. The tunica media, the middle layer, consist predominately of 
VSMCs and external elastic lamina. VSMCs are responsible for vasoconstriction and 
dilation of the blood vessel. The outermost layer, known as the tunica adventitia, 
predominately consists of loose connective tissue, which is made up of fibroblasts and 
collagen fibers, and small blood vessels (vasa vasorum). 
Vascular disease involves the activation of many cell types including endothelial 
cells, vascular smooth muscle cells (VSMCs), macrophages, mast cells, lymphocytes, and 
neutrophils.3 Endothelial dysfunction is a primary event in vascular disease. Endothelial 
cells are activated due to metabolic risk factors, thereby causing blood monocytes to 
permeate the endothelial cell layer and infiltrate the intima and subintima layer of the 
artery. During this process monocytes mature into macrophages resulting in their uptake 
of lipids, yielding foam cells. VSMCs migrate from the media to the intima, proliferate, 
secrete extracellular matrix (ECM), resulting a plaque formation. Necrosis of lipid-
containing foam cells and VSMCs result in a necrotic core formation. Dead and dying 
cells accumulate in the region creating a fibrous cap, predominately composed of smooth 
muscle cells and macrophages. The last step, thrombosis, involves the rupture of the 
fibrous cap. Highly thrombogenic components of the necrotic core and tissue factors 
come into contact with circulating monocytes in the blood, initiating a thrombus in the 
vessel. 
VSMCs exhibit a diverse range of phenotypes. In normal physiological 
conditions, VSMCs are maintained in a quiescent “contractile” or differentiated 
phenotypic state, which is necessary for contraction and dilation of the blood vessel. 
During this quiescent state, VSMCs express a repertoire of VSMC markers, including 
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smooth muscle cell myosin heavy chain (MYH11), calponin 1 (CNN1), smooth muscle 
22 alpha (SM22α), and alpha smooth muscle actin (αSMA). These established VSMC 
differentiation markers contain a CC(A/T-rich)6GG (CArG) element and a transforming 
growth factor β (TGF-β) control element within the promoter/enhancer regions. 
However, under pathological conditions, VSMCs will undergo a phenotypic transition 
from quiescent state to a proliferative, non-contractile state or “synthetic” state. These 
synthetic VSMCs will lose their expression of VSMCs markers, known as 
dedifferentiation, and exhibit high rates of proliferation, migration and production of 
ECM proteins and cytokines. This transition is known as a phenotypic modulation or 
plasticity, and first originated in the 1960s from an ultrastructural characterization of 
VSMC culture.4 In their synthetic state, VSMCs can migrate to the intima and proliferate 
following vascular injury. The phenotypic modulation of VSMCs is a innate property of 
differentiated VSMCs, which presumably evolved from higher species as an adaptation 
for survival. However, an exorbitant degree of VSMC plasticity can result in adverse 
vascular remodeling and disease. The synthetic phenotype of VSMCs, increased 
proliferation, and increased migration and ECM secretion are key elements in lesion 
formation. As such, a fine-tuning of VSMC phenotypic transition is necessary to regulate 
the development and progression of vascular disease. 
It is proposed that the dysfunction of vascular stem cells (VSCs) is essential in the 
pathogenesis of vascular disease. An active state of adult VSCs may be an indication of 
maladaptive vascular remodeling caused by the loss of quiescence and consequent 
activation of VSCs. Therefore, a quiescent status of adult resident VSCs may be critical 
for the repair of a damaged vasculature.5 The current understanding of adult resident 
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VSCs is somewhat rudimentary. Adult resident VSCs are believed to originate from 
embryogenesis. These cells are necessary for vascular development and remain within the 
vasculature after birth for post-natal growth, aging and disease.6 These cells remain 
quiescent until activated by vascular injury or disease. Given their close proximity, they 
are quickly recruited to the site of injury for self-renewal and differentiation.7 These 
stem/progenitor cells have very distinct phenotypes and appear in different compartments 
in the vessel wall – the intima, media and adventitia. The characterization of these adult 
resident VSCs remains unclear, due to the discrepancies in multiple reports. However, 
what is clear is that these adult resident VSCs have the potential to differentiate to SMCs, 
ECs, and pericytes. This is evident by their upregulation lineage specific cell markers 
after stimulation with various growth factors and chemokines. In addition, these VSCs 
have adipogenic, chondrogenic, osteogenic, leiomyogenic and angiogenic potential. 
Although there are currently no established markers, Sca-1 is a primary marker used to 
identify adult resident VSCs in the murine vasculature. Multiple reports also indicate that 
these resident VSCs can contribute to vascular lesion formation rather than repair. Many 
aspects regarding resident VSCs and progenitor cells remain to be addressed, such as 
their profile, location, method of isolation, culture conditions, and animal injury models, 
as well as the mechanisms that control their differentiation and function. A full evaluation 
of adult resident VSC contribution to vascular remodeling cannot be performed without 
considering all of these factors. Most importantly, addressing these aspects may connect 
with the discrepancies in the multiple reports. Further investigation of molecular 
mechanisms for controlling the functional states of resident VSCs may unravel the nature 
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of resident VSCs per se as well as the precise contributions of VSC-mediated vascular 
lesion formation and repair. 
 
1.3 MOLECULAR MECHANISMS REGULATING VASCULAR SMOOTH MUSCLE 
CELL PLASTICITY: 
The phenotype modulation or plasticity of VSMCs plays a crucial role in the 
development of vascular diseases. Therefore, the elucidation of the molecular 
mechanisms regulating VSMC phenotypic modulation could provide some insight into 
the development of vascular diseases. The phenotypic switching of VSMCs in vascular 
disease is regulated by a multitude of environmental cues/signals, which will be 
discussed in three categories: 1. Epigenetic mechanisms, 2. Genetic mechanisms, 3. 
Protein quality control. 
1. EPIGENETIC MECHNANISMS 
A preceding level of regulation in SMC gene expression must occur to 
account for the array of genes involved in the regulation of VSMC phenotype 
modulation, rather than solely one gene. Transcriptional gene activation is 
controlled by chromatin remodeling and histone modifications. This hierarchal 
level of gene activation provides an additional layer of transcriptional control, 
independent of RNA or DNA sequence, and is referred to as epigenetic 
mechanism of gene regulation. An extensive amount of research has been 
conducted to determine the epigenetic mechanism of VSMC phenotypic 
modulation in vascular disease. 
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Histones are a group of proteins that package DNA in nucleosomes. The 
histone complex is an octamer which is assembled by two sets of protein-protein 
interactions: H2A, H2B, H3, and H4. The acetylation of histones is a major 
epigenetic mechanism in gene regulation. It involves the addition or removal of 
acetyl groups from lysine residues on the histone N-terminal tails and is regulated 
by histone acetyltransferases (HATs) and histone deacetylases (HDACs), 
respectively. HATs add acetyl groups to histones, which promote chromatin 
unfolding and make DNA more accessible for transcriptional gene activation. 
HDACs reserve these effects by removal of acetyl groups from histones.  
It was reported that HDAC transcription is increased in response to 
mitogenic stimulation of VSMCs and is required for proliferation by regulating 
G1-S phase cell cycle progression. HDAC inhibition induced cell cycle arrest by 
preventing mitogen-induced retinoblastoma protein phosphorylation, and also 
repressing mitogen-induced cyclin D1 mRNA expression and cyclin D1 
transcription. Furthermore, HDAC inhibition reduced neointimal formation and 
cyclin D1 expression following vascular injury.8 
It has also been reported that acetylation at H3 and H4 residues are 
enriched at SMC gene CArG boxes, and display high levels of H3 Lys4 and 
Lys79 dimethylation (H3K4dMe and H3K79dMe, respectively) in SMCs relative 
to non-SMC lineages.9 In conclusion, epigenetic modifications at the CArG 
region represent an important site for the phenotypic modulation of VSMCs.  
2. Genetic Mechanisms 
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Serum response factor (SRF), a MADS box transcription factor, and its 
co-activator myocardin bind to CArG boxes to initiate transcription of VSMC 
genes in response to pathological environmental cues in culture and in vivo. It 
was reported that myocardin interacted with H3K4dMe and selectively enhanced 
SRF binding to CArG box chromatin of SMC genes, resulting in the upregulation 
of SMC differentiation markers.9 Therefore, the control of SRF/myocardin 
binding to CArG boxes represents a major mechanism in the phenotypic 
modulation of VSMCs in vascular remodeling. 
Krüppel-like factor 4 (KLF4) is a transcriptional repressor that has also 
been found to play a role in the regulation of VSMC phenotype. KLF4 also acts as 
a potent repressor of VSMC phenotype modulation by binding to the transforming 
growth factor beta (TGF-β) control element within the promoter/enhancer regions 
of VSMC differentiation markers.10 Furthermore, it interacts with SRF and 
represses the expression of SRF co-activator myocardin and disrupt acetylation of 
histone H4.9,11,12 
Platelet-derived growth factor (PDGF) is a potent chemoattractant released 
by activated platelets and many cell types including, ECs, macrophages, and 
VSMCs from neointimal lesions. PDGF was shown to be a negative regulator of 
VSMC markers, in vitro, and also stimulates VSMC proliferation and migration 
by attenuating SRF/myocardin binding to VSMC CArG boxes. It was 
demonstrated that KLF-4 is induced after PDGF-BB exposure. Also, suppression 
of KLF4 by small interfering approach partially blocked PDGF-BB-induced SMC 
gene repression. It was also determined that morphogen Sonic hedgehog (SSh) 
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mediates PDGF-induced VSMC phenotypic modulation in cultured VSMCs 
through regulation of KLF4.13 Taken together, these results suggest that KLF4 
might act as key effector in PDGF-BB-induced repression of VSMC 
differentiation markers. 
Current studies are now aimed at determining the role of KLF4 in VSMC 
phenotype modulation, in vivo. KLF4, which is not normally expressed in 
differentiated SMCs, was rapidly upregulated in vivo in response to vascular 
injury. This was the first evidence suggesting of KLF4 involvement in vascular 
remodeling.12 Since KLF4 knockout mice result in early post-natal death14, SMC-
targeted conditional KLF4 knockout mice were developed to determine the role of 
KLF4 in vivo. It was shown that VSMC-specific conditional knockout of KLF4 
markedly reduced lesion size, and increased fibrous cap thickness thereby causing 
plaque stability.10 Therefore, the KLF4-dependent SMC phenotypic modulation 
may be of critical importance the pathogenesis of vascular disease. 
The deubiquitinating enzyme cylindromatosis (CYLD) is a critical 
regulator of many cellular processes, via the regulation of nuclear factor kappa B 
(NF-κB)-mediated inflammation.  Our lab was able to demonstrate a novel role of 
CYLD in mediating pro-inflammatory responses in VSMCs, via a NF-κB-
independent manner. Knockdown of CYLD, by adenoviral approach, decreased 
tumor necrosis factor alpha (TNFα)-induced pro-inflammatory cytokines 
monocyte chemotactic protein-1 (Mcp-1), intercellular adhesion molecule 
(ICAM-1) and interleukin-6 (IL-6) in rat aortic smooth muscle cells (RASMCs). 
Furthermore, CYLD knockdown also suppressed TNFα-induced activation of 
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mitogen activated protein kinases (MAPKs), extracellular signal-activated kinases 
(ERK), c-Jun N-terminal kinases (JNK) and p38. Interestingly, CYLD expression 
was increased in injured coronary artery afflicted with neointimal hyperplasia.15 
Overall, these results suggest a pro-inflammatory role of CYLD in VSMCs via 
MAPK activation and NF-κB-independent activation, thereby contributing to the 
pathogenesis of vascular disease. 
3. Protein Quality Control 
Apoptosis is a process of programmed cell death that occurs during 
normal development. Several environmental and endogenous factors have been 
identified in the apoptosis of VSMCs in the development of vascular disease. 
These factors include reactive oxygen and nitrogen species, cytokines, growth 
factors, and oxidized lipoproteins. Other factors that play a role in the initiation 
and progression of VSMC apoptosis include the Fas/Fas ligand/caspase death-
signaling pathway, Bcl-2 protein family/mitochondria, the tumor suppressive gene 
p53, and the proto-oncogene c-Myc. 
The Fas/Fas ligand/caspase death-signaling pathway plays an important 
role in the in the induction of apoptosis in neointimal lesions. Both Fas/Fas 
ligands have been shown to be expressed in neointimal VSMCs.  Notably, 
overexpression of Fas ligand, by adenovirus approach, was shown to inhibit 
neointimal formation following balloon injury.16 
 The infiltration of immune cells within neointimal lesions also play a role 
in the apoptosis of VSMCs. Immune cells, such as macrophages and T 
lymphocytes, can produce inflammatory cytokines such as TNF and interferon-
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gamma (IFN-γ), which can secrete nitric oxide (NO), thereby inducing apoptosis 
of VSMCs in cell culture. NO can attack iron-containing enzymes involved in 
DNA synthesis and mitochondrial respiration, thereby leading to apoptosis of 
target cells, such as VSMCs.17 It was demonstrated that macrophage-induced NO 
can activate VSMC apoptosis via Fas ligand pathway. Human plaque derived 
VSMCS underwent apoptosis when co-cultured with monocytes/macrophages. 
However, this effect was inhibited by neutralizing antibodies to Fas ligand.18 In 
addition, NO inhibitor blocked NO production by macrophages and reduced 
VSMC apoptosis in response to macrophage induced NO.19 
 Tumor suppressive gene p53, and the proto-oncogene c-Myc were also 
shown to be involved in VSMC apoptosis. Adenovirus-mediated transfer of p53 
induced apoptosis which resulted in atherosclerotic plaque rupture.20 Fas itself has 
also been shown to be mediated by p53. In addition, NO-induced apoptosis of 
VSMCs include downstream mediators p5321 and Fas.22 It was also shown that 
deregulated expression of c-Myc oncogene abolishes inhibition of proliferation of 
VSMCs and induces apoptosis with various stimuli 23 Moreover, overexpression 
of p53 induces apoptosis in rat VSMCs infected with c-MYC but not normal cells 
24 
Oxidized lipoproteins (OxLDL) can also induce VSMC apoptosis in 
neointimal lesions thereby contributing to plaque instability and rupture. OxLDL 
was localized to neointimal lesions as well as medial-derived VSMCs that 
coexpress proapoptotic protein Bax.25 Consistent with this study, high OxLDL 
can induce apoptosis of VSMCs via the Bax/Bcl-2 and lectin-like OxLDL 
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receptor-1 in VSMCs.26 As such, the molecular mechanisms causing OxLDL-
induced apoptosis may be involved in the destabilization and rupture of 
atherosclerotic plaques. 
Autophagy is another important physiological process, which results in the 
destruction of cells by lysosomal compartments. While autophagy is necessary for 
normal vascular function, it has also been found to play a role in vascular disease, 
due to the dysfunction of SMCs.27 PDGF induces autophagy in VSMCS 
independent of AMP-activated protein kinase (AMPK) and mammalian target of 
rapamycin (mTOR). PDGF-induced autophagy also promoted the downregulation 
of VSMC differentiation markers resulting in a synthetic phenotype, and 
increased the proliferation and migration of VSMCs.28 SSh, which has already 
been identified as a mediator in PDGF-induced VSMC differentiation, also 
induced autophagy via protein kinase B (AKT) activation. Notably, treatment 
with autophagy inhibitor 3-methyladenine, AKT inhibitor, or Shh receptor 
cyclopamine significantly reduced neointimal formation in mouse carotid arteries 
after ligation.29 Taken together, these results suggest a critical role of autophagy 
in the pathogenesis of vascular disease due to the phenotype modulation of 
VSMCs. 
 
1.4 CYCLIN-DEPENDENT KINASE 8: 
Cyclin-dependent kinases (CDKs) are traditionally characterized by their role in 
cell cycle progression; however, there also exist a set of CDKs that are directly involved 
in regulation of RNA polymerase II (RNAPII). These CDKs are known as transcriptional 
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kinases. CDK8 exist within the family of transcriptional kinases. CDK8 is a part of the 30 
subunit Mediator (MED) complex, which acts as a molecular bridge between DNA-
binding transcription factors and RNAPII. The MED consists of the head, middle, tail, 
and the CDK8 submodule. The head is composed of subunits MED6, MED8, 11, 17-20, 
22, 28, the middle subunits are MED1, 4, 7, 9, 10, 14, 21, 26, 3/27, 31, the tail subunits 
are MED15, 16, 23-25, 2/29. CDK8 consist within the CDK submodule consisting of 
CDK8 (or its paralog CDK19), cyclin C, MED12 and MED13. It is well established that 
MED is important for the pre-initiation complex since it interacts with RNAPII, thereby 
influencing the transcription initiation process. 
The MED complex also joins to transcription factors bound at upstream 
regulatory elements such as nuclear receptors, and transcription machinery (RNAPII, the 
general initiation factor TFIIA, -IIB, IID, IIE, IIF, and –IIH, DNA-binding transcription 
factors) and transcription coactivators, at the promoter region, thereby controlling 
epigenetic regulation, transcriptional initiation and elongation, transcriptional 
termination, mRNA processing, noncoding RNA activation, and the chromatin 
remodeling.30,31 Given its plethora of functions, the MED complex can be seen as a mass 
coordinator of development and cell lineage determination. Several components of the 
MED complex have been shown to cause embryonic lethality, such as MED1, MED12, 
MED21, MED23, MED24, MED31 and CDK8.31 As such, gene knockdown approaches 
of MED subunits have been employed to investigate MED deficiencies. Knockdown 
mice or targeted inactivation of other subunits, such as MED1, MED12, MED14, 
MED19, MED25, MED26 and MED28 and CDK8, indicated that these subunits play an 
essential role in specific gene expression programs during differentiation and 
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organogenesis. These subunits are also associated with cardiovascular diseases. Specific 
MED subunits (MED1, MED12, MED13/13L, MED14, MED 15, MED23, MED25, 
MED30, and CDK8) have been shown to be associated with congenital malformations, 
such as congenital heart diseases.31 However, the precise role and interplay of Mediator 
components and modules in cardiovascular pathologies still remain unclear. More 
recently CDK8 has been shown to be a key component in the regulation of the MED 
complex, making it a topic of interest. 
CDK8 is a nuclear serine-threonine kinase that can regulate transcription. The 
majority of evidence regarding CDK8 is based on its association with MED complex; 
however, only a fraction of CDK8 exists outside of this complex. It has been proposed 
that up to 30% of CDK8 can exist and function independently of the MED complex. 
Biochemical analysis of recombinant CDK8 identified RNAPII and TFIIH, as well as 
histone H3, MED13, and CDK8 as substrates for the CDK8 kinase. It was also revealed 
that MED12, but not MED13, is essential for human CDK8 kinase activity.32,33 
Furthermore, mass spectrometry analysis revealed CDK8 to be associated with DNA-PK, 
GCN1L1 and TRiC chaperonin, which may help in controlling its biological function.32 
However, the biological significance of DNA-PK, GCN1L1, and TRiC association 
requires further elucidation. 
Traditionally, CDK8 has been depicted as transcriptional repressor, however 
much of this knowledge has been limited to research in yeast and metazoan cells. More 
recent evidence demonstrates that CDK8 is also positive regulator in transcription. 
Moreover, CDK8 has been shown to be a coactivator in many molecular pathways linked 
to stem cells and cancer. These pathways include the β-catenin pathway, the p53 
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pathway, the serum response network, the TGF-β signaling pathway, and thyroid 
hormone-dependent transcription. Given its dual role in transcription, as a positive and 
negative regulator, CDK8 can be deemed as a master regulator of transcription. 
There are several reports of CDK8 as a negative regulator of transcription. The 
most initial evidence of CDK8 as a co-repressor was shown in yeast. SRB10, the CDK8 
homolog in yeast, was shown to phosphorylate the RNAPII CTD at Ser2 and Ser5 prior 
to PIC assembly, thereby, inhibiting transcription.34 However, this has not been 
confirmed in vivo and the mechanism remains to be elucidated. 
SRB10 was also shown to inhibit transcription by promoting nuclear export or 
degradation of specific transcriptional activators, such as Gcn4, the multistress response 
transcriptional factor Msn2, and Ste2.35,36 SRB10 can phosphorylate Gcn4 marking it for 
degradation by SCFCdc4 for ubiquitin ligase. Msn2 is also a substrate for SRB10 and is 
translocated to the nucleus by heat-induced stress via hyper-phosphorylation in an 
SRB10-dependent manner.35 Another substrate, Ste2, promotes the filamentous growth of 
budding yeast Saccharomyces cervisiae in nutrient limiting conditions. SRB10 inhibits 
filamentous growth via phosphorylation of Ste2, thereby decreasing its stability. 
Furthermore, nitrogen limiting conditions resulted in loss of SRB10 protein, as well as 
kinase activity, and corresponding loss of Ste2 phosphorylation.36 These results conclude 
that SRB10 can employ a variety of regulatory mechanisms to coordinate gene 
expression with growth potential. 
Microarray results in yeast revealed that while most MED subunits play a positive 
role through activator-mediated recruitment and interaction with RNAPII, the CDK-
module is predominately a negative regulator of transcription.37 These results reinforce 
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this traditional view of CDK8 as an antagonist of transcription, at least in lesser organism 
such as yeast. 
In higher organisms, it was also demonstrated that human CDK8 can inhibit 
transcription via phosphorylation and inactivation of the cyclin H subunit of TFIIH.38 
Specifically, CDK8 phosphorylation of TFIIH phosphorylates mammalian cyclin H at the 
amino-terminal and carboxy-terminal alpha-helical domains. This phosphorylation 
repressed TFIIH to activate transcription and its CTD kinase activity.38 
In addition, co-activation assays in vitro, demonstrated that human CDK8-MED is 
less active than the core MED complex, and recombinant CDK module can block the 
core MED co-activator function.39–41 However, it’s inhibition was independent of CDK8 
activation, most likely due to MED12 and MED13 components.41 Furthermore, 
compensatory mechanisms for gene activation involved less CDK8-Mediator and more 
core-Mediator for MAPK-dependent activation of the transcription factor C/EBPβ, and 
retinoic acid-induced activation of the RARβ2 gene.42,43 
A previous study by Zhao et al reported that CDK8 and cyclin C are negative 
regulators of lipogenesis in Drosophila and mammalian cells. CDK8 phosphorylation of 
SREB-1c transcription factor at threonine residue (Thr) resulted in an increase in SREBP-
1c ubiquitination and protein turnover, thereby leading to inhibition of lipogenesis.44 
While several reports indicate SRB10/CDK8 as a negative regulator in yeast, it is 
also seen as a positive transcriptional regulator in yeast. For example, genome-wide 
chromatin immunoprecipitation (ChIP) studies demonstrated that CDK8 was present in 
active and inactivated genes, thus suggesting that CDK8 can promote transcription.45  It 
was also shown that SRB10 phosphorylation of GAL4 at serine 699, is necessary for 
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galactose-inducible transcription, and this transcription occurs concurrently with the 
transactivation of general initiation factors.46 Furthermore, yeast CDK7 homolog, KIN28, 
and SRB10 work together to promote RNAPII transcription and scaffold complex 
formation by ATP-dependent dissociation of the PIC.47 This study also demonstrated 
SRB10 phosphorylates two subunits of TFIID (BDF1 and TAF2) and KIN28 
phosphorylates two subunits of MED complex (MED4 and MED14).47 In summary, the 
aforementioned studies reveal SRB10/CDK8 is also as a positive regulator of 
transcription in yeast. 
In mammalians, CDK8 is a stimulus specific co-activator of p53-dependent 
transcription.48,49 The p53 gene is a tumor suppressive protein involved in cell-cycle 
arrest and apoptosis. The induction of cell-cycle arrest by p53 is activated by cyclin-
dependent kinase inhibitor p21. Several studies have demonstrated that p21 is activated 
by p53 upon Nutlin 3 treatment. Donner et al demonstrated that CDK8, along with cyclin 
C and MED12, are recruited to p21 locus exclusively after Nutlin 3 treatment.49 
Additionally, CDK8 recruitment correlates with positive transcriptional activity among 
p53 target genes, Hdm2 and p21. RNA interference studies further confirmed that CDK8 
is indeed a positive regulator of p53 target genes.49 
CDK8 was also shown to be a positive regulator of thyroid hormone receptor-
dependent transcription. Belakavadi demonstrated that CDK8 cooperates with MED 
complex in thyroid hormone receptor-dependent transcription by promoting RNAPII 
recruitment and activation of thyroid hormone-receptor target genes.50 It was further 
demonstrated that CDK8 kinase activity is important for thyroid hormone dependent 
transcription in vivo. ChIP assays revealed significant levels of CDK8 at the thyroid 
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hormone receptor human type I deiodinase (DIOI) gene promotor during active 
transcription. Additionally, CDK8 knockdown prevented thyroid hormone-dependent 
activation of DIOI. Finally, CDK8 depletion was rescued with a wild type CDK8, but not 
a kinase-dead mutant.50 
It was also shown that CDK8 Enhances SMAD transactivation.33,48,51 TGF-β and 
BMP receptor kinases activated SMAD transcription factors by C-terminal 
phosphorylation, and subsequent translocation to the nucleus with SMAD4 where they 
form transcriptional complexes of TGF-β- and bone morphogenetic factor (BMP)-
regulated genes. In the cytoplasm phosphorylation of receptor-activated SMADs in the 
linker region led to proteasomal degradation.48 However, TGF-β and BMP activation led 
to agonist-induced linker phosphorylation in the nucleus by CDK8 and CDK9. This was 
due to CDK8 and CDK9 enhancement of receptor-activated SMADs by promoting co-
activator recruitment.51 
Recent studies indicate that CDK8 is a potential oncogene in colon cancer. Wnt/ 
β-Catenin signaling plays and important role in colon cancer.48,52,53 Upon activation, Wnt 
signaling leads to stabilization of β-Catenin allowing its translocation to the nucleus and 
formation of transcription complexes with TCF/LEF at Wnt-responsive genes such as 
MYC and Cyclin D1. Loss of function studies identified CDK8 to be highly expressed in 
human colon cancer cells. Suppression of CDK8 expression inhibited proliferation of 
colon cancer cells while exhibiting high levels of CDK8 and β-Catenin hyperactivity.52 
CDK8 was also found to associate with MYC promoter and knockdown of CDK8-
module subunits MED12 and cyclin C had a similar outcome to CDK8 knockdown, 
suggesting that CDK8 collaborates with the CDK8-module to stimulate β-Catenin 
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transcription.52 It still remains unclear whether CDK8 acts directly on the β-
Catenin/TCF/LEF complex or on the general transcriptional apparatus. CDK8 can also 
play a role in β-Catenin activity through transcriptional factor E2F1. E2F1 is a 
transcriptional regulator, which can promote proliferation and apoptosis.  It was reported 
that E2F1 represses β-Catenin transcription and is antagonized by CDK8 
phosphorylation. Furthermore, both CDK8 and E2F1 were at the MYC promoter. 54 
Overall, these results demonstrate the positive effects of CDK8 on β-Catenin 
transcriptional activity, and its inhibitory effect on E2F1. 
CDK8 promotes RNAPII elongation within the serum response network. 
Mitogen-driven activation of the RAS/RAF/MEK/ERK pathway leads to transcription of 
ELK1-dependent serum responsive genes.55 CDK8 promotes the recruitment of 
transcription elongation factor, P-TEFb, providing a mechanism by which CDK8 can 
positively affect transcription post-RNAPII recruitment steps.56 
It was also revealed that CDK8 catalyzes histone modifications that correlate with 
transcriptional activation. Biochemical assays revealed that cdk8-Mediator complex 
associates with TRRAP and GCN5L polypeptides. Interestingly, the CDK8 and GCN5L 
subunits within this ‘T/G-Mediator' complex work together to catalyze tandem 
phosphoacetylation of S10/K14 within histone H3.57 Since tandem H3 
phosphoacetylation correlates with active transcription, these results identify a role for 
CDK8 in transcriptional activation. 
The aforementioned studies support the role of CDK8 as positive and negative 
regulator of transcription, from yeast to mammals. In summary, CDK8 was shown to be 
involved in the regulation of transcription factor turnover, CTD phosphorylation and 
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transcriptional activation or repression. CDK8 was also shown to regulate several 
transcriptional programs involved in nutrient/growth factor sensors and differentiation 
control, thus making it a potential therapeutic target.5 
Alder et al demonstrated that CDK8 is required for tumor growth in vivo and 
maintains tumors in a less differentiated state. Furthermore, CDK8 maintains embryonic 
stem cell pluripotency, and this effect was partially mediated via the MYC pathway.58 In 
this study, CDK8 inhibition resulted in little to no change in MYC mRNA levels, 
suggesting that MYC is regulated post-transcriptionally. The regulation of MYC activity 
involves priming the protein for degradation or transcriptional activation by 
phosphorylation (p) on threonine 58 (T58) and serine 62 (S62), respectively.59,60 CDK8 
inhibition by gene knockdown revealed an increase in the unstable MYC-pT58 and a 
decrease in the active MYC-pS62, relative to total MYC. Exogenous expression of either 
wild-type MYC or degradation resistant MYCT58A in embryonic stem cells increased 
MYC levels compared to control cells and partially rescued the loss of embryonic stem 
cell pluripotency imparted by CDK8 depletion. Conversely, expression of MYCS62A, 
which disrupts the active phosphorylation site, increased total MYC levels but was 
unable to rescue the loss in pluripotency, suggesting that CDK8 regulation of embryonic 
stem cell pluripotency is partially mediated through MYC activity.58 Overall, these 
results revealed that CDK8 might be positioned at a crossroad of tumorigenesis and stem 
cell fate. It also raises the intriguing possibility that therapeutically targeting CDK8 may 
inhibit the stem cell-like properties of cancer cells. 
Porter et al recently discovered a small molecule inhibitor of CDK8 and its 
isoform CDK19, though inhibition of p21-induced transcription.61 The inhibitor, known 
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as Senexin A, inhibits CDK8 kinase activity by binding to the ATP pocket site. Of note, 
Senexin A does not affect normal cell growth. Interestingly, the inhibitor was found to 
suppress chemotherapy-induced tumor promoting paracrine activities of normal and 
tumor cells. Moreover, the inhibitor also increased the efficacy of chemotherapy against 
tumor cell xenografts. 61 Overall, these results identify CDK8 as a druggable mediator of 
disease-promoting paracrine activities involved in DNA damage and senescence. 
Therefore, CDK8 inhibition offers a potential therapeutic target for the inhibition of these 
actions in cancer and other related diseases, such as vascular disease. 
CDK8 resides upstream for transcription and therefore it might play a specific 
role in coordinating genome expression in VSMC differentiation and remodeling. As 
stated previously, some components of the MED complex have already been shown to be 
involved in cardiovascular disease53 ; however, the extent of CDK8 involvement remains 
to be determined.  Based on these results, my overall hypothesis is that CDK8 is a critical 
mediator in SMC dedifferentiation and vascular lesion formation. My aims are as 
follows: 
1. To explore the role of CDK8 in SMC dedifferentiation. 
2. To determine the molecular mechanisms by which CDK8 regulates SMC 
dedifferentiation. 
3. To determine the role of CDK8 in SMC-mediated vascular remodeling in mice. 
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CHAPTER 2 
CYCLIN-DEPENDENT KINASE 8 IS A POSITIVE REGULATOR IN 
VASCULAR SMOOTH MUSCLE CELL DEDIFFERENTIATON 
2.1 INTRODUCTION: 
Occlusive vascular disease, characterized by abnormal proliferation and 
accumulation of vascular SMCs in the vascular lesion, is one of the most common causes 
of morbidity and mortality in USA.62 Over the last decades, extensive studies including 
the genetic inducible fate mapping experiments have convincingly supported a working 
hypothesis that after vascular injury, mature and quiescent vascular SMCs undergo 
dedifferentiation, also known as phenotype modulation or switch. This process is 
characterized by a downregulation or loss of expression of contractile genes, such as 
smooth muscle myosin heavy chain (MYH11), smooth muscle 22 alpha (SM22α), 
calponin-1 (CNN1), and alpha smooth muscle actin (αSMA), and a concomitant with an 
increase in cell proliferation, migration, and extracellular matrix (ECM) production, 
thereby leading to vascular lesion formation.63–69 At the molecular level, mechanical 
stress, a number of ligand-receptor interactions, and ECM-sensing machineries drive 
intricate pathways at multiple levels of the gene expression regulation
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70–73 and/or the protein quality control74 thus contributing to vascular SMC 
dedifferentiation. It is becoming clear, however, that these mechanisms are necessary for 
complete control of vascular SMC physiology and pathophysiology. The master 
regulators of vascular SMC dedifferentiation, which are druggable for the treatment of 
vascular disease, remain to be determined. 
 CDK8 and its closely related paralog CDK19 (80% identical) are transcription-
regulating serine/threonine kinases with a functional overlap in the transcriptional 
regulation.75 CDK8 is a component of the Mediator (MED) complex, which consists of 
four distinct modules termed the head, middle, tail and CDK8 kinase module. In 
mammals, Mediator complex has several subtypes with the most canonical one composed 
of around 30 subunits to form the head (MED6, MED8, 11, 17-20, 22, 28), middle 
(MED1, 4, 7, 9, 10, 14, 21, 26, 3/27, 31), tail (MED15, 16, 23-25, 2/29), and the 
regulatory CDK8 module (CDK8/19, CCNC, MED12, and MED13) and joins 
transcription factors bound at the upstream regulatory elements and the transcription 
machinery (PolI, the general initiation factor TFIIA, -IIB, IID, IIE, IIF, and –IIH, DNA-
binding transcription factor and transcription coactivators) at the promoter region, 
thereby controlling epigenetic regulation, transcriptional initiation and elongation, 
transcriptional termination, mRNA processing, noncoding RNA activation, and the 
chromatin remodeling.30,48 Multiple approaches including gene knockout technology in 
mice have revealed a general requirement for Mediator in coordinating the cell lineage 
determination, development, and metabolism, which are potentially linked to 
cardiovascular diseases.30,31 However, the precise role and interplay of Mediator 
components and modules in cardiovascular pathologies are unclear. On the other hand, 
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emerging evidence has indicated that CDK8 is not likely to regulate the expression of 
stably expressed genes,48 and instead acts primarily to enable the elongation of 
transcription of silent genes that become activated by transcription-induced 
factors.51,52,56,76 In addition, CDK8 can indirectly regulate gene expression through 
directly phosphorylating its protein substrates, such as receptor activated SMADs, E2F1, 
STAT1, and p27, and likely independently of Mediator complex formation.51,54,76–79 
Moreover, the conditional knockout of CDK8 throughout the body of adult mice does not 
induce gross or histopathological abnormalities.80 These results indicate that CDK8-
operated signaling may not be essential for somatic cellular homeostasis, but play a 
unique role in the pathological processes, such as the cell transformation for cancer61, 
leading to diseases. Therefore, we questioned whether or not CDK8 is a yet unrecognized 
regulator of vascular SMC dedifferentiation for occlusive vascular remodeling. In this 
report, we demonstrate that CDK8 is a critical mediator of vascular SMC 
dedifferentiation. 
To investigate the role of CDK8 in SMC dedifferentiation, we used a primary 
culture of rat aortic SMCs (RASMCs) and tested the effects of CDK8 inhibition by 
utilizing a specific inhibitor of CDK8, Senexin A61, and lentivirus of CDK8 shRNA. We 
also tested the effect of CDK8 overexpression by adenoviral approach. We hypothesized 
that CDK8 inhibition will promote SMC differentiation by suppressing RASMC 
proliferation, enhance SMC marker expression, and inhibit SMC migration and ECM 
secretion. Conversely, CDK8 overexpression will promote SMC dedifferentiation by 
increasing RASMC proliferation and decrease SMC protein marker expression. In the 
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current study we demonstrate that CDK8 is a positive regulator of vascular SMC 
dedifferentiation. 
 
2.2 MATERIALS AND METHODS: 
Animals:  
Male Sprague Dawley (SD) rats (6-8 weeks old) were purchased from Jackson 
Laboratories. All animals were housed at the AAALAC-accedited University of South 
Carolina School of Medicine. All animal procedures were performed in accordance with 
NIH Guideline for Care and Use of Laboratory Animals and were approved by the 
Institutional Animal Care and Use Committee of University of South Carolina School of 
Medicine. 
Human Specimens: 
Tissue sections of arteries were prepared from autopsy organ specimens of humans with 
cardiovascular disease history (Appendix A.1). This study was approved by the 
Institutional Review Board for human subject research at Icahn School of Medicine at 
Mount Sinai, New York. 
RASMC Isolation: 
Briefly, SD rats were euthanized by intraperitoneal injection by an overdose of 
pentobarbital (100 mg/kg) before tissue collection. The thoracic aortas were removed, 
washed in phosphate-buffered saline (PBS) and incubated in 1g/L Dulbecco’s modified 
Eagle’s medium (DMEM) containing 7.5 mg Collagenase type II (Worthington 
Biochemical Corp. Cat. 17101-015) for 30 min. Using a dissection microscope, the 
surrounding connective tissue and adventitia were removed. The dissected tunica media 
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tissues were incubated for 2-3 hours with 7.5 mg Collagenase type II and minced 
periodically throughout incubation. Cells were cultured in conventional regular growth 
medium (RGM) containing 10% Fetal bovine serum (FBS) in DMEM and 100 μg/mL 
penicillin/streptomycin in a 37 °C and 5% CO2 humidifed chamber. 
Reagents and Antibodies: 
The reagents used in this study were purchased as described below: 
Senexin A/B from Senex Biotechnology (Columbia, SC), [H3] Thymidine (Cat #: 240-
3905, Millipore, Billerica, MA), Ad-Green fluorescent protein (GFP) (Cat#: 1060, Vector 
Biolabs, Burlingame, CA), and Ad-c-Myc (Cat#: 1285, Vector Biolabs, Burlingame, 
CA), Ecolite (Cat#:882475, Millipore, Bilerica, MA). 
The following antibodies were purchased from Abcam (Cambridge, MA): c-MYC 
(ab32072, GFP (ab6673), SM22α (ab14106), CNN1 (ab46974), αSMA (ab5694). 
The following antibodies were purchased from Santa Cruz (Santa Cruz, CA): c-MYC 
(sc40), Ubiquitin (sc-8017), JNK (sc571), CDK8 (sc1521). 
The following antibodies were purchased from Sigma Aldrich (St. Louis, MO): B-actin 
(a1978), GAPDH (a8795), αSMA (A5228), MYH11 (ab125884). 
Quantitative real-time PCR (qPCR): 
Total cellular RNA was purified with TRIzol (Invitrogen). Gene expression was 
measured by qPCR, and normalized by concurrent measurement of glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) mRNA levels. Primers for qPCR included SM22α 5’–
CCACAAACGACCAAGCCTTTT–3’ and 5’–CGGCTCATGCCATAGGATG–3’, Cnn1 
5’–ACATCATTGGCCTACAGATG–3’ and 5’– CAAAGATCTGCCGCTTGGTG–3’, 
Myh11 5’–CGGTGTTCTCCTGCTAGTCC–3’ and 5’– 
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CTTCTTGGCTACCCAGTCGG–3’, Mmp2 (matrix metalloproteinase-2) 5’–
GACCTTGACCAGAACACCATCG–3’ and 5’–GCTGTATTCCCGACCGTTGAAC–3- 
and Gapdh 5’–AGTGCCAGCCTCGTCTCATA–3’ and 5’–
GATGGTGATGGGTTTCCCGT–3’, OPN (Ostepontin) 5’– 
AAGGCGCATTACAGCAAACACTCA–3’ and 5’– 
CTCATCGGACTCCTGGCTCTTCAT –3’ 
Lentiviral Transfection: 
pLKO.1 and CDK8 lentivirus was provided by Dr. Igor Roninson (University of South 
Carolina School of Pharmacy, Columbia, SC). CDK8 lentivirus was generated as 
previously described (Porter et al., 2012). Knockdown of CDK8 was generated by 
transduction with pLKO.1 lentiviral vectors expressing the corresponding shRNAs (Open 
Biosystems), followed by puromycin selection (2.5 μg/ml). The target sequences for 
CDK8 shRNA was GTCTTATCAGTGGGTTGATTC. 
Proliferation Studies: 
Isolated RASMCs (p1-p10) were seeded at 10,000 cells/well on 24-well plate in RGM 
with 10% FBS. Thereafter, RASMCs were serum starved for 16 hr. The following day, 
RASMCs were treated with vehicle dimethyl sulfoxide (DMSO) 5 μm Senexin A/B for 0 
- 9 days and proliferation was measured by a hemocytometer. 
[H3]Thymidine Assay: 
Isolated RAMCs (p1-p10) were seeded at 40,000 cells/well on a 24-well plate in RGM 
with 10% FBS. Thereafter, RASMCs were serum starved for 16 hr. RASMCs were 
treated with vehicle dimethyl sulfoxide (DMSO) 5 μm Senexin A for 24 hours, with 
[3H]thymidine (1 μCi/ml) being added during the last 4 hours of culture. RASMCs were 
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washed with ice cold 5% TCA overnight. The following day, RASMCs were washed 
with ice cold 5% TCA, two times, and washed with 1x PBS, two times. RASMCs were 
lysed with 0.5 ml of 0.5M NaOH for 30 min in a 37 °C and 5% CO2 humidifed chamber. 
Cells were added to Ecolite (2ml/well). DNA synthesis was measured by [3H]thymidine 
uptake via a liquid scintillation counter. 
Differentiation Assay: 
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes in RGM with 10% FBS and 
grown to 80-90% confluence. Thereafter, RASMCs were serum starved (DMEM alone) 
for 16 hr. The following day, RASMCs were treated with the appropriate treatments for 
48 hours. After treatment, RASMCs were subjected to Western blot analysis using SMC 
differentiation markers. 
Migration Assay: 
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes. RASMCs were serum 
starved for 2 days, treated for the following three days. Treatments included 5 μm 
Senexin A and 10% FBS. P200 pipet tip was used to create a scratch at the bottom of 
each well and the cells were incubated further for 3 days. The distance between the edges 
of the scratch was measured immediately after scratching and again after the time point 
day 3. Migration was quantified and expressed as follows: % closure = [(distance 
immediately after scratching – distance after 3 days)/distance immediately after 
scratching] * 100. Microscopic pictures were taken using Infinity 3 microscope camera. 
Western blot: 
Protein extracts were prepared by standard procedures. Immunoblotting 
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was conducted by enhanced chemiluminescence using Western Lightning Plus-ECL 
(Perkin-Elmer). 
Cell Cycle Analysis: 
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes in RGM with 10% FBS and 
grown to 80-90% confluence (n=3 per treatment). Thereafter, RASMCs were serum 
starved (DMEM alone) for 16 hr. The following day, RASMCs were treated with the 
appropriate treatments for 48 hours. After treatment, cells were harvested by trypsin 
method and subjected to flow cell cycle analysis. Briefly, RASMCs were centrifuged for 
10 min at 1000 rpm at 25 °C in the medium. Media was aspirated. RASMCs were then 
washed with 5 ml PBS and centrifuged for 10 min at 1000 rpm. Media was aspirated. 500 
ul of ice-cold 70% ETOH was added dropwise. Samples were stored in -80 °C until 
analysis. Cells were centrifuged at 1000 rpm for 5 min and ETOH was aspirated. 1 ml of 
propidium iodine staining solution was added to cells on ice for 30 min. Samples were 
then analyzed on Beckson Dickson Flow Cytometer. PI staining solution consisted of 200 
ug/ml PI and 2mg/ml DNase-free Rnase A. 
Statistics: 
Data are shown as mean ± SEM. Differences between 2 groups were evaluated for 
statistical significance using the Student t test when the sample size was appropriate and 
the population was distributed normally. When differences among > 3 groups were 
evaluated, results were compared by one-way ANOVA with Bonferroni test for multiple 




Upregulation of CDK8 in Injured Arteries: 
To explore a potential role of CDK8 in the vasculature, we examined the 
expression pattern of CDK8 in mouse normal and injured arteries. Confocal microscopic 
analysis revealed that CDK8 is mainly expressed in endothelial cells and media SMCs in 
the normal carotid artery (Figure 2.1). However, the expression of CDK8 was increased 
on 3 day and then decreased to near to the basal level on 28 day after complete carotid 
ligation (Figure 2.2). In addition, the carotid ligation induced CDK8 expression in 
adventitial cells with a similar pattern aforementioned (Figure 2.2). CDK8 expression 
was also evident in NI cells on 28 day after the injury, although it was relatively low 
(Figure IB). Western blot showed that CDK8 expression in the carotid artery was 
increased on 3 day and then decreased to near to the basal level on 28 day after complete 
carotid ligation (Figure 2.3). Since previous lineage-tracing studies have demonstrated 
that the majority of NI cells are not derived from endothelial cells but mature vascular 
SMCs68,81 and mature vascular SMCs undergo dramatic dedifferentiation on 3 day82 in 
the carotid ligation model, these results suggest that CDK8 may play an important role in 
the regulation of vascular SMC dedifferentiation and NI formation. Importantly, CDK8 
expression was significantly upregulated in SMCs in the atherosclerotic plaque of human 
carotid arteries (Figure 2.4). These findings highlight a pathological relevance of CDK8 
in vascular disease. 
 
A Mediator Role of CDK8 in Vascular SMC Dedifferentiation: 
To investigate whether or not CDK8 regulates vascular SMC dedifferentiation, 
we used a primary culture of rat aortic SMCs (RASMCs), a well-established  culture 
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system of dedifferentiated vascular SMCs.64 We found that SMC contractile proteins 
including MYH11, αSMA, and CNN1 were dramatically downregulated in cultured 
SMCs compared with SMCs in the tunica media, indicating a dedifferentiated state as 
described elsewhere64 ; however, the CDK8 expression was significantly upregulated in 
the dedifferentiated RASMCs (Figure 2.5). Inhibition of CDK8 activity via lentiviral 
knockdown approach or a highly selective small molecule inhibitor of CDK8, Senexin 
A61 attenuated cell number increases of RASMCs cultured in a full growth medium 
(Figure 2.6) and FBS-induced [3H]-thymidine uptake in RASMCs (Figure 2.7) associated 
with delayed progression through all phases of the cell cycle including G0/G1, S, and 
G2/M phases (Figure 2.8) and increased expression of SMC contractile proteins including 
αSMA, CNN1, and SM22α (Figure 2.9). The specificity of Senexin A was verified in 
RASMCs (Figure 2.10). Senexin A treatment suppressed migration as well as the 
expression of matrix metalloproteinase-2 (Mmp2) and osteopontin (Opn) while 
upregulating the expression of SMC contractile proteins including Myh11, Cnn1, and 
Sm22α in cultured RASMCs (Figure 2.11 and 2.12). These results demonstrate that 
CDK8 is a critical mediator of vascular SMC dedifferentiation with typical synthetic 
phenotypes including increased proliferation, migration, and secretion. 
 
2.4 DISCUSSION: 
CDK8 has been shown to be of importance in cancer cells and embryonic 
cells.58,61 However, our results uncover, for the first time that CDK8 is normally 
expressed in endothelial cells and vascular SMCs, thus suggesting that CDK8 is 
expressed under normal physiological conditions in the vasculature. Moreover, CDK8 
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was shown to be upregulated in dedifferentiating vascular SMCs suggesting that CDK8 
may play a role in the pathological process of vascular disease. Mature vascular SMCs 
undergo a dedifferentiation, also known as phenotype modulation or switch. This process 
plays a critical role in vascular lesion formation and is characterized by a downregulation 
or loss of expression of contractile genes and a concomitant with an increase in cell 
proliferation, migration, and extracellular matrix production,.67,83 CDK8 inhibition was 
able to regulate all three events by promoting increased proliferation, migration and ECM 
secretion as well as promoting a synthetic phenotype. Therefore, we can conclude that 
CDK8 acts as a mediator in SMC dedifferentiation and can potentially be a therapeutic 
target in the treatment of vascular disease. Further studies are needed to investigate the 
molecular mechanism by which CDK8 regulates SMC dedifferentiation as well as the 
pathological relevance of CDK8, in vivo. Nonetheless, these results provide a significant 




Figure 2.1. CDK8 is expressed in media SMCs in normal carotid artery. Confocal 
microscopic analysis of CDK8 in normal male adult mice in C57BL/6J background. L, 
lumen; M, media. 
 
 
Figure 2.2. CDK8 expression is upregulated after carotid ligation injury in mice. Male 
adult mice in C57BL/6J background (n=10 for eac h group) were induced with cartoid 
artery ligation and CDK8 expression was analyzed by confocal microscopy at day 3 and 





Figure 2.3. CDK8 protein expression is upregulated after carotid ligation injury in mice. 
Male adult mice in C57BL/6J background (n=10 for each group) were induced with 
cartoid artery ligation and CDK8 protein expression was analyzed by Western blot 





Figure 2.4. CDK8 is expressed in human coronary arteries with atherosclerotic lesions. 
The images shown are representative of CDK8 staining in tissue sections of human 
coronary arteries with atherosclerotic lesions (n=6). IEL, internal elastic lamina; EEL, 
external elastic lamina; Ad, adventitia. 
 
 
Figure 2.5. CDK8 protein expression is upregulated in RASMC cell culture. RGM-
cultured RASMCs at 11 days (passage 3) and the tunica media lysates (isolated from the 
thoracic aorta of male SD rats at age of 10 weeks) were subjected to Western blot 
analysis of CDK8 expression and SMC markers MYH11, αSMA, and CNN1. 




Figure 2.6. CDK8 inhibition reduced RASMC proliferation. A. Serum starved lentiviral 
RASMCs were cultured in RGM for 0-9 days and proliferation was measured by a 
hemocytometer (n=3). B. Serum starved RASMCs at early passage were cultured in 10% 
FBS-supplemented media with 5 μm Senexin A for 0 – 9 days and proliferation was 
measured by a hemocytometer (n=3). 
 
 
Figure 2.7. CDK8 inhibition reduced DNA synthesis. A. RASMCs were lentivirally 
transduced with scramble vector or shCDK8 and cultured in RGM. Serum starved 
lentiviral RASMCs were treated as indicated for 24 h and subjected to [3H]-thymidine 
uptake assay to measure DNA synthesis. B. RASMCs without lentiviral transduction 
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were treated with 2.5µM and 5µM Senexin A for 24 h and subjected to [3H]-thymidine 
uptake assay to measure DNA synthesis. n=6, *p<0.05 vs. control (-). 
 
 
Figure 2.8. CDK8 inhibition prevented RASMC cell cycle progression at g0/g1 phase. 
Serum starved RASMCs at early passage were treated as indicated for 48 h and subjected 
to flow cytometry cell cycle analysis (n=3). 
  
 
Figure 2.9. CDK8 inhibition promoted RASMC differentiation. A. RASMCs were 
lentivirally transduced with scramble vector or shCDK8 and cultured in RGM. Serum 
starved RASMCs were treated with 10% FBS for 10 minutes and subjected to Western 
blot analysis of SMC protein markers (αSMA, CNN1 and SM22α) and CDK8. B. Serum 
starved post-confluent RASMCs were stimulated with 10% FBS and 5 μM Senexin A for 
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48 hours. Western blot was conducted to determine the expression of SMC protein 
markers (αSMA and CNN1). Representative results are from 3 separate experiments. 
 
 
Figure 2.10. Senexin A reduction on DNA synthesis is CDK8 specific. RASMCs were 
lentivirally transduced with scramble vector or shCDK8 and cultured in RGM. Serum 
starved lentiviral RASMCs were treated as indicated for 24 h and subjected to [3H]-




Figure 2.11. CDK8 inhibition attenuated FBS-induced migration of RASMCs. Serum 
starved RASMCs at early passage were treated as indicated for 72 h and subjected to 
migration assay. A. Pictures were taken via Infinity 3 microscope software. B. Migration 
was quantified and expressed as follows: % closure = [(distance immediately after 




Figure 2.12. Senexin A treatment increased extracellular matrix secretion. Serum starved 
RASMCs (48 h) were treated with 20 ng/ml PDGF-ββ and 5 μM Senexin A (Sen A) for 
24 h and qRT-PCR analysis was conducted to determine the relative mRNA expression 




CYCLIN-DEPENDENT KINASE 8 IS A POSITIVE REGULATOR IN 
VASCULAR SMOOTH MUSCLE CELL DEDIFFERENTIATION VIA 
AKT/GSK3β-MEDIATED ENHANCMENT OF C-MYC 
STABILIZATION 
3.1 INTRODUCTION: 
Occlusive vascular disease, characterized by abnormal proliferation and 
accumulation of vascular SMCs in the vascular lesion, is one of the most common causes 
of morbidity and mortality in USA.62 Upon vascular disease, SMCs will dedifferentiate 
from a quiescent, contractile state with high expression of SMC markers to a 
proliferative, synthetic state with low expression of SMC markers, thereby causing lesion 
formation.63–69 This process is known as SMC dedifferentiation. At the molecular level, 
mechanical stress, a number of ligand-receptor interactions, and extracellular matrix-
sensing machineries drive intricate pathways at multiple levels of the gene expression 
regulation70–73 and/or the protein quality control74 thus contributing to vascular SMC 
dedifferentiation. It is becoming clear, however, these mechanisms are necessary for 
complete control of vascular SMC physiology and pathophysiology. The master 
regulators of vascular SMC dedifferentiation, which are druggable for the treatment of 
vascular disease, remain to be determined.
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 CDK8 is a transcriptional kinase that has been involved in several regulatory 
pathways. A recent study identified CDK8 as a druggable mediator of disease-promoting 
paracrine activities involved in DNA damage and senescence. Therefore, CDK8 
inhibition offers a potential therapeutic target for the inhibition of these actions in cancer 
and other related diseases, such as vascular disease.  
CDK8 inhibition resides upstream for transcription and therefore it might play a 
specific role in coordinating genome expression in VSMC differentiation and 
remodeling. In fact, our previous studies demonstrate that CDK8 is a positive regulator in 
SMC dedifferentiation, resulting in increased cell proliferation and the downregulation of 
SMC protein marker expression and an increase in FBS-induced migration and ECM 
secretion. However, the molecular mechanisms that regulate CDK8-mediated SMC 
dedifferentiation remains to be determined.  
CDK8 has been shown to regulate several signaling pathways that are key 
regulators in embryonic stem cell pluripotency, cancer, and presumably cardiovascular 
disease.31,48,58,61 The oncoprotein c-MYC has been identified an important regulator in 
tumor dedifferentiation and embryonic stem cell pluripotency. c-MYC resides 
downstream of other target genes, which CDK8 has been shown to regulate. However, 
upstream target genes of c-MYC have yet to be identified. It is possible that CDK8-
mediated SMC dedifferentiation is ultimately regulated by c-MYC. Therefore, we 
hypothesized that CDK8 is a critical meditator of SMC dedifferentiation via the c-Myc 
pathway.   
To investigate the molecular mechanisms in CDK8-mediated SMC 
dedifferentiation, we used a primary culture of rat aortic SMCs (RASMCs) and tested the 
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effects of CDK8 inhibition by utilizing a specific inhibitor of CDK8, Senexin A61, and 
lentivirus of CDK8 shRNA, and performed several signaling studies analyzed by Western 
blot. We also tested the effect of c-MYC overexpression by adenoviral approach and 
performed another set of signaling studies analyzed by Western blot. We hypothesized 
that CDK8 plays a role in RASMC dedifferentiation via c-MYC pathway.  In this report, 
we demonstrate that CDK8 is an upstream operator of AKT/GSK3β signaling for c-MYC 
stabilization leading to vascular RASMC dedifferentiation. 
 
3.2 MATERIALS AND METHODS: 
Animals:  
Male Sprague Dawley (SD) rats (6-8 weeks old) were purchased from Jackson 
Laboratories. All animals were housed at the AAALAC-accredited University of South 
Carolina School of Medicine. All animal procedures were performed in accordance with 
NIH Guideline for Care and Use of Laboratory Animals and were approved by the 
Institutional Animal Care and Use Committee of University of South Carolina School of 
Medicine.  
RASMC Isolation: 
Briefly, SD rats were euthanized by intraperitoneal injection by an overdose of 
pentobarbital (100 mg/kg) before tissue collection. The thoracic aortas were removed, 
washed in phosphate-buffered saline (PBS) and incubated in 1g/L Dulbecco’s modified 
Eagle’s medium (DMEM) containing 7.5 mg Collagenase type II (Worthington 
Biochemical Corp. Cat. 17101-015) for 30 min. Using a dissection microscope, the 
surrounding connective tissue and adventitia were removed. The dissected tunica media 
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tissues were incubated for 2-3 hours with 7.5 mg Collagenase type II and minced 
periodically throughout incubation. Cells were cultured in conventional regular growth 
medium (RGM) containing 10% FBS in DMEM and 100 μg/mL penicillin/streptomycin 
in a 37 °C and 5% CO2 humidifed chamber. 
Reagents and Antibodies: 
The reagents used in this study were purchased as described below:  
Senexin A/B from Senex Biotechnology (Columbia, SC), GSK3β inhibitor (SB-216763, 
Cat#: S3442, Sigma-Aldrich, St. Louis, MO), AKT inhibitor (MK-2206, Cat#: 1032350-
13-2, Sigma Aldrich, St. Louis, MO), Epoxomicin (Cat #: E3652, Sigma Aldrich, St. 
Louis, MO), [H3], Ad-GFP (Cat#: 1060 Vector Biolabs, Burlingame, CA), and Ad-c-
Myc (Cat#: 1285, Vector Biolabs, Burlingame, CA). 
The following antibodies were purchased from Cell Signaling Technologies (Beverly, 
MA): pAKT T308 (CST 9275S), p-AKT S473 (CST 9271S), AKT (CST 9272S), AKT 
(CST 2920), p-GSK3β (CST 9323P), GSK3β (CST 9315), p-ERK Thr202/Tyr04 (CST 
9101S), ERK (CST 9102), p-JNK Thr183/Tyr185 (CST 9251), p-p38 Thr180/Tyr182 
(CST 9211S), p38 (CST 9212), p-STAT1 Ser727 (9177), STAT1 (CST 9172). 
The following antibodies were purchased from Abcam (Cambridge, MA): c-MYC 
(ab32072), GFP (ab6673), SM22α (ab14106), CNN1 (ab46974), αSMA (ab5694), 
MYH11 (ab125884). 
The following antibodies were purchased from Santa Cruz (Santa Cruz, CA): c-MYC 
(sc40), Ubiquitin (sc8017), JNK (sc571), CDK8 (sc1521) 
The following antibodies were purchased from Sigma Aldrich (St. Louis, MO): B-actin 
(a1978), GAPDH (a8795), αSMA (a5228). 
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The following antibody was purchased from ProteinTech Group (Rosemont, IL): CDK8 
(22067-1-AP). 
Adenoviral Transfection: 
Early passage (p) RASMCs (p1-p10) were transfected with Ad-GFP or Ad-cMyc 
according to manufacturer’s protocol. 20 MOI of Ad-GFP or Ad-cMyc was added in SF 
medium, and cells were incubated for 6 hrs in a 37 °C and 5% CO2 humidifed chamber. 
Transfected cells were re-fed fresh media DMEM supplemented with 2% FBS. After 48 
hours, the transfected cells were harvested by trypsinization and re-seeded on the 
appropriate petri dishes for future studies.  
Lentiviral Transfection:  
pLKO.1 and CDK8 lentivirus was provided by Dr. Igor Roninson (University of South 
Carolina School of Pharmacy, Columbia, SC). CDK8 lentivirus was generated as 
previously described (Porter et al., 2012). Knockdown of CDK8 was generated by 
transduction with pLKO.1 lentiviral vectors expressing the corresponding shRNAs (Open 
Biosystems), followed by puromycin selection. The target sequences for CDK8 shRNA 
was GTCTTATCAGTGGGTTGATTC. 
Cell Signaling Studies: 
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes in RGM with 10% FBS and 
grown to 80-90% confluence. Thereafter, RASMCs were serum starved (DMEM alone) 
for 16 hr. The following day, RASMCs were treated with the appropriate treatments for 
10 or 30 minutes. For some studies RASMCs were pre-treated with 0.1 μM Epoxomicin, 
4 nM and 8 nM AKT inhibitor, or 0.01 μM  GSK3β inhibitor for 1-2 hours. After 
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treatment, RASMCs were subjected to Western blot analysis of potential signaling 
pathways involved.  
Proliferation Studies: 
Isolated RASMCs (p1-p10) were seeded at 10,000 cells/well on 24-well plate in RGM 
with 10% FBS. Thereafter, RASMCs were serum starved for 16 hr. The following day, 
RASMCs were treated with vehicle control, dimethyl sulfoxide (DMSO), and 5 μm 
Senexin A for 0 - 9 days and proliferation was measured by a hemocytometer.  
[H3]Thymidine Assay: 
Isolated RAMCs (p1-p10) were seeded at 40,000 cells/well on a 24-well plate in RGM 
with 10% FBS. Thereafter, RASMCs were serum starved for 16 hr. RASMCs were 
treated with vehicle dimethyl sulfoxide (DMSO) 5 μm Senexin A/B for 24 hours, with 
[3H]thymidine (1 μCi/ml) being added during the last 4 hours of culture. RASMCs were 
washed with ice cold 5% TCA overnight. The following day, RASMCs were washed 
with ice cold 5% TCA, two times, and washed with 1x PBS, two times. RASMCs were 
lysed with 0.5 ml of 0.5M NaOH for 30 min in a 37 °C and 5% CO2 humidifed chamber. 
Cells were added to Ecolite (2ml/well). DNA synthesis was measured by [3H]thymidine 
uptake via a liquid scintillation counter.  
Differentiation Assay: 
Isolated RASMCs (p1-p10) were seeded on 6-cm petri dishes in RGM with 10% FBS and 
grown to 80-90% confluence. Thereafter, RASMCs were serum starved (DMEM alone) 
for 48 h. The following day, RASMCs were treated with the appropriate treatments for 48 
hours. After treatment, RASMCs were subjected to Western blot analysis using SMC 
differentiation markers.  
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Quantitative real-time PCR (qPCR): 
Total cellular RNA was purified with TRIzol (Invitrogen). Gene expression was 
measured by qPCR, and normalized by concurrent measurement of glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) mRNA levels. Primers for qPCR include c-Myc 5’ –
TCCTCGCGTTATTTGAAGCCT-3’ and 5’–CGAGTCGTAGTCGAGGTCAT–3’, and 
Gapdh 5’–AGTGCCAGCCTCGTCTCATA–3’ and 5’–
GATGGTGATGGGTTTCCCGT–3’.  
Immunoprecipitation, Immunoblotting and Immunohistochemical Analyses: 
The protein expression in cells and tissues were analyzed by immunoblotting and 
immunohistochemical staining as we previously reported 83,84. The protein-protein 
association in the cell was examined by immunoprecipiation and immunoblotting as well 
as confocal microscopic analysis as we previously reported 83–85. 
Statistics: 
 Data are shown as mean ± SEM. Differences between 2 groups were evaluated for 
statistical significance using the Student t test when the sample size was appropriate and 
the population was distributed normally. When differences among > 3 groups were 
evaluated, results were compared by one-way ANOVA with Bonferroni test for multiple 
comparisons. Differences were considered significant at p < 0.05. 
 
3.3 RESULTS: 
A Critical Role of CDK8 in Activating AKT/GSK3β Pathway and Stabilizing c-MYC in 
Vascular SMCs: 
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Recently, c-MYC and STAT1, the established mediators of vascular SMC 
dedifferentiation,86–90 have emerged as downstream effectors of CDK8 in stem cells 58 
and immune cells, respectively.78,79 Hence, we extrapolated these findings into cultured 
RASMCs. We found that Senexin A did not affect STAT1 phosphorylation at Ser727, the 
previously identified phosphorylation site of CDK8 in immune cells,78,79 but 
downregulated c-MYC protein expression (Figure 3.1). The inhibitory effect of Senexin 
A was further verified by lentiviral knockout of CDK8 (Figure 3.2). These results 
indicate that c-MYC may be a downstream effector of CDK8 in mediating vascular SMC 
dedifferentiation. Since CDK8 inhibition did not affect c-Myc mRNA expression level 
(Figure 3.3) and could not lead to the downregulation of c-MYC anymore in the presence 
of a proteasome inhibitor, Epoxomicin (Figure 3.4 and 3.5), it is most likely that CDK8 
upregulates c-MYC expression via a posttranscriptional mechanism that stabilizes c-
MYC proteins in vascular SMCs. 
 It has been demonstrated that in the normal cell, c-MYC protein is rapidly 
degraded following its synthesis with a half-life of ~20 min and the most prominent route 
for c-MYC degradation is through the ubiquitin proteasome system (UPS).91 In addition, 
the c-MYC degradation is regulated by multiple Ras effector pathways.91 The most 
studied pathways are the Raf-MEK-ERK kinase cascade and the PI3K-AKT pathway that 
inhibits GSK3β. The ERK and GSK3β phosphorylate two sites of c-MYC, i.e., Ser62 and 
Thr58, respectively. The phosphorylation at Ser62 results in c-MYC stabilization. The 
phosphorylation at Ser62 is also required for the subsequent phosphorylation of c-MYC 
at Thr58 by GSK3β, which is associated with c-MYC degradation. Hence, we examined a 
potential role of CDK8 in regulating the MAPK and AKT/GSK3β signaling for c-MYC 
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stabilization in cultured RASMCs. Interestingly, not the serum-induced phosphorylation 
of MAPKs including ERK, JNK and p38, but the phosphorylation of AKT and its 
downstream effector GSK3β was inhibited by Senexin A (Figure 3.6). In addition, CDK8 
inhibition led to increases in ratios of p-c-MYC (Thr58)/β-actin in both serum-starved 
and serum-stimulated RASMCs (Figure 3.7). These results indicate that CDK8 promotes 
the activation AKT to suppress GSK3β-mediated phosphorylation of c-MYC at Thr58 for 
degradation in vascular SMCs. 
 
A Novel Signaling Axis of CDK8-AKT Activation-GSK3β Inhibition-c-MYC 
Stabilization for Vascular SMC Dedifferentiation: 
Previous studies have shown that AKT and GSK3β may either promote or 
suppress vascular SMC dedifferentiation and NI formation.92–95 Accordingly, we 
determined the contribution of AKT and GSK3β to the CDK8 mediated stabilization of c-
MYC and phenotype modulation in cultured RASMCs. A dose-response study revealed 
that AKT specific inhibitor MK-2066 (a highly selective inhibitor of AKT1/2/3 with 
IC50 of 8 nM/12 nM/65 nM, respectively) at doses from 4 nM to 3 µM dose-dependently 
suppressed FBS-induced phosphorylation of AKT (Thr308 and Ser473) and GSK3β 
(Ser9) and upregulation of c-MYC (Figure 3.8 and Figure 3.9). MK-2066 (0.65 µM) also 
inhibited FBS-induced cell number increases (Figure 3.10) as recently reported.96 The 
Senexin A-induced suppression of AKT (Thr308) and GSK3β (Ser9) phosphorylation, c-
MYC expression, and increased proliferation were additively enhanced by MK-2066 
(Figure 3.9 and 3.10). Like Senexin A, MK-2066 also inhibited FBS-induced 
downregulation of CNN1 protein expression (Figure 3.11), which is in consistent with a 
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recent report which shows AKT inhibitor induced suppression of vascular SMC 
dedifferentiation in vivo.95 Moreover, MK-2066 and Senexin A additively suppressed the 
FBS-induced downregulation of SMC contractile protein expression (Figure 3.11). These 
results indicate that CDK8 is an upstream operator of AKT/GSK3β signaling for c-MYC 
stabilization leading to vascular SMC dedifferentiation. To verify the notion, we used 
GSK3β specific inhibitor SB-216763 (IC50, 0.343 µM) at a dose of 0.01 µM, which was 
verified to maximally promote RASMC proliferation presumably due to the specific 
suppression of GSK3β-induced c-MYC degradation (Figure 3.12). These results are 
consistent with a previous report which shows GSK3β–dependent inhibitory effects on 
vascular SMC proliferation and NI formation.93 Of note, the GSK3β inhibitor SB-216763 
at doses from 0.01 µM to 25 µM was capable of upregulating AKT phosphorylation on 
both Thr308 and Ser473; however, at effective doses lower than 1 µM, SB-216763 
upregulated c-MYC protein levels while at the doses higher than 10 µM, it 
downregulated c-MYC protein expression (Figure 3.12 upper and Figure 3.13). These 
results indicate that GSK3β inhibitor SB-216763 at doses higher than 1 µM could not 
inhibit GSK3β-mediated c-MYC degradation and instead may trigger c-MYC 
downregulation via yet known off-target effects in vascular SMCs. In addition, GSK3β 
acts as a negative regulator of AKT phosphorylation in vascular SMCs. Indeed, the 
pharmacological inhibition of GSK3β-mediated c-MYC degradation attenuated the 
inhibitory effect of Senexin A on c-MYC expression and cellular proliferation while 
suppressing the Senexin A-induced upregulation of SMC marker expression (Figure 
3.13-3.15). Moreover, the Senexin A-induced growth inhibitor effect and upregulation of 
SMC contractile gene expression were also largely reversed by overexpression of c-MYC 
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(Figure 3.16). To this end, our findings collectively demonstrate that CDK8 activates 
AKT to suppress GSK3β-mediated c-MYC degradation thereby promoting RASMC 
dedifferentiation. 
 
An Inhibitor Role of CDK8 in AKT Subcellular Compartmental Translocation for 
Activation in Vascular SMCs: 
Although AKT signaling has been well implicated in vascular SMC biology and 
pathology, the molecular mechanisms for AKT activation in vascular SMCs are largely 
extrapolated from the other studies.97 Accordingly, it has been assumed that in response 
to mitogen stimulation, AKT is translocated to the plasma membrane and then 
phosphorylated on two key residues, Thr308 and Ser473, by 3-phosphoinositide-
dependent protein kinase-1 (PDK-1) and mammalian target of rapamycin complex 2 
(mTORC2) respectively, leading to AKT activation. Following activation, AKT detaches 
from the plasma membrane and translocates into the cytosol and nucleus to trigger its 
downstream signaling. To explore whether or not CDK8 interrupts the aforementioned 
signaling events for AKT activation in vascular SMCs, we determined a potential 
interaction between CDK8 and AKT in cultured RASMCs by confocal microscopy as 
well as immunoprecipitation (IP) and immunoblotting (IB) analyses. In the serum-starved 
SMCs, AKT was expressed in the nucleus, cytosol, and membrane, whereas CDK8 is 
expressed predominantly in the nucleus (Figure 3.17). Upon serum stimulation, AKT was 
translocated to the plasma membrane and the nucleus; however, CDK8 was translocated 
to the cytosol (Figure 3.17). Interestingly, inhibiting CDK8 activity via Senexin A (Sen 
A) enhanced the cytosolic translocation of CDK8 while suppressing AKT membrane and 
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nuclear translocation associated with AKT peri-nuclear accumulation (Figure 3.17). 
Notably, CDK8 was co-localized with AKT in the nucleus and peri-nuclear region 
(Figure 3.17). These results suggest that CDK8 physically associates with AKT to 
promote its translocation to both the plasma membrane and nucleus thereby facilitating 
AKT activation and AKT-driven signaling in vascular SMCs. Indeed, IP/IB studies 
revealed that CDK8 associated with AKT in the serum-starved SMCs and the CDK8 and 
AKT association was enhanced by serum stimulation; however, this association depended 
on CDK8 activity (Figure 3.18). Collectively, these results demonstrate that CDK8 kinase 
activity is critical for its association with AKT thereby activating AKT and AKT-driven 
signaling in vascular SMCs. 
 
3.4 DISCUSSION: 
Our previous studies demonstrate a critical role of CDK8 in SMC 
dedifferentiation with typical synthetic phenotypes including increased proliferation, 
migration and ECM secretion; however, the molecular mechanism by which CDK8 
regulates SMC dedifferentiation was not addressed. In the present study we identified a 
novel signaling axis of CDK8-AKT activation-GSK3β inhibition-c-MYC stabilization in 
mediating SMC dedifferentiation. We uncovered that: activation of CDK8 promotes the 
activation AKT to suppress GSK3β-mediated phosphorylation of c-MYC at Thr58 for 
proteasomal degradation in RASMCs; CDK8 activates AKT to suppress GSK3β-
mediated c-MYC degradation thereby promoting RASMC dedifferentiation; and CDK8 
kinase activity is critical for its association with AKT thereby activating AKT and AKT-
driven signaling in vascular SMCs.However, the precise mechanism by which CDK8 
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mediates vascular SMC dedifferentiation was not completely delineated in this study. 
Similar to Sen A drug treatment, AKT inhibitor MK-2066 (with IC50 of 8 nM/12 nM/65 
nM, respectively) also inhibited FBS-induced downregulation of SMC markers CNN1 at 
4nM dosage. Since the selected dosage was much lower than the recommonded IC50 
dosage for AKT1 inhbition, it is mostly likely ATK1, can inhibit GSK3β-mediated c-
MYC degradation, thereby promoting vascular SMC dedifferentiation. Further studies 
will need to be conducted to confirm the role of isoform AKT1 in SMC dedifferentation. 
Moreover, the observed CDK8-c-MYC signaling axis may not be the sole mechanism for 
facilitating vascular SMC dedifferentiation. Considering the observation that CDK8 
primarily enabled the elongation of transcription of silent genes that become activated by 
transcription-induced factors,51,52,56,76 usually in the pathological setting 98, it is possible 
that CDK8 may also control the transcription of a group of genes for vascular SMC 
dedifferentiation. Further investigation of these subjects will lead to a better 




Figure 3.1. Senexin A treatment downregulated c-MYC protein expression but had no 
effect on STAT1 phosphorylation. Serum starved RASMCs were treated with 10% FBS 
and 5 μM Sen A for 30 min then subjected to Western blot analysis. Representative 
results are from 3 separate experiments. 
 
 
Figure 3.2. CDK8 inhibition by lentiviral approach reduced c-MYC protein expression. 
Serum starved RASMCs were treated with 10% FBS and 5 μM Sen A for 30 min then 





Figure 3.3. CDK8 inhibition did not affect c-Myc mRNA expression level. Serum starved 
RASMCs (24 h) were treated with 10% FBS and 5 μM Sen A for 30 min then subjected 
to qRT-PCR to determine relative c-Myc mRNA expression. Representative results are 
from 3 separate experiments. 
 
 
Figure 3.4. Senexin A treatment reduces c-MYC protein level of RASMCs by ubiquitin 
proteasomal degradation. Serum starved RASMCs were pre-treated with proteasome 
inhibitor, Epoxomicin at 0.1 μM, for 24 h and treated with 10% FBS and 5 μM Sen A for 
30 min then subjected to Western blot analysis for c-MYC protein expression. 




Figure 3.5. The efficacy of Epoxomicin on proteasome function in cultured RASMCs. 
Serum starved RASMCs were pre-treated with 0.1 μM Epoxomicin and 10% FBS for 24 




Figure 3.6. The effect of CDK8 inhibitor Senexin A on FBS-induced activation of 
MAPKs (ERK, JNK and p38) and AKT. Serum starved RASMCs were treated with 10% 
FBS and 5 μM Sen for 10 minutes and subjected to Western blot analysis of potential 




Figure 3.7. CDK8 inhibitor Senexin A increased c-MYC phosphorylation. Serum starved 
RASMCs were treated with 10% FBS and 5 μM Sen for 30 minutes and subjected to 




Figure 3.8. The dose-response of AKT inhibitor (AKT-I) MK-2066 on FBS-induced 
activation of AKT, inhibition of GSK3β, and upregulation of c-MYC. Serum starved 
RASMCs were treated with 10% FBS and 5 μM Sen for 30 minutes and subjected to 




Figure 3.9. CDK8 inhibitor Senexin A and AKT inhibitor MK-2066 behave similarly in 
FBS-induced activation of AKT/GSK3β pathway for c-MYC stabilization. Serum starved 
RASMCs were treated with 10% FBS, 5 μM Sen, and 8 µM MK-2066 for 30 min and 





Figure 3.10. AKT inhibitor, MK-2066, inhibited FBS-induced cell proliferation. Serum 
starved RASMCs at were treated with 10% FBS, 5 um Senexin A, or 0.65 µM MK-2066 
for 24 h and subjected to [3H]-thymidine uptake assay to measure DNA synthesis. 





Figure 3.11. The effect of AKT inhibitor (AKT-I) and Senexin A on FBS-induced 
downregulation of SMC contractile proteins. Serum starved RASMCs at were treated 
with 10% FBS, 5 um Senexin A, and 4 nM MK-2206 (AKT-I) for 48 h and subjected to 
Western blot. The upper panel shows representatives of immunoblots from 3 separate 
experiments. The lower panel shows the semi-quantified results of CNN1 protein 
expression. * p<0.05 vs. the control (-) in the same group. 
 
 
Figure 3.12. GSK3β inhibitor (GSK3β-I) SB-216763 can dose-dependently regulate AKT 
activity, GSK3 β activity, and c-MYC stability in cultured RASMCs, thereby affecting 
RASMC proliferation. A. Serum starved RASMCs were treated in 10% FBS with 
GSK3β-I at various dosages for 30 min and subjected to Western blot anaylsis of PI3K-
AKT signaling casade. B. Serum starved RASMCs were treated in RGM with various 
dosages of GSK3β inhibitor (GSK3β-I) SB-216763 and the proliferation was measured 
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Figure 3.13. CDK8 inhibitor Senexin A and GSK3β-I have opposing effects on FBS-
induced activation of AKT/GSK3β pathway for c-MYC stabilization. Serum starved 
RASMCs were treated with 10% FBS, 5 μM Sen, and 0.01 μM GSK3β-I (SB-216763) 





Figure 3.14. GSK3β inhibitor (GSK3β-I) SB-216763 increased FBS-induced cell 
proliferation. Serum starved RASMCs at were treated with 10% FBS, 5 um Senexin A, 
and 0.01 µM GSK3β-I (SB-216763) for 24 h and subjected to [3H]-thymidine uptake 




Figure 3.15. GSK3β inhibitor (GSK3β-I) SB-216763 and Senexin A have opposing 
effects on FBS-induced downregulation of SMC contractile protein markers in cultured 
RASMCs. Serum starved RASMCs were treated with 10% FBS, 5 μm Senexin A, and 
0.01 µM GSK3β-I (SB-216763) for 48 h and subjected to Western blot. The upper panel 
shows representatives of immunoblots from 3 separate experiments. The lower panel 
shows the semi-quantified results of SM22α and CNN1 protein expression. * p<0.05 vs. 




Figure 3.16. Adenoviral overexpression of c-MYC attenuated the effect of Senexin A 
(Sen A) on RASMC proliferation and SMC contractile protein CNN1 expression. 
RASMCs were adenovirally transduced with adenoviral GFP or adenoviral c-MYC and 
cultured in RGM. A. Serum starved adenoviral RASMCs at were treated as indicated 3 
days and measured by a hemocytometer (n=3). B. Adenoviral RASMCs were subjected 
to Western blot analysis of GFP and c-MYC protein markers. C. Adenoviral RASMCs 
treated with 10% FBS and 5 μM Sen A for 48 h and subjected to Western blot analysis. 




Figure 3.17. The effect of CDK8 inhibitor Senexin A on FBS-induced AKT membrane 
and nuclear translocation. A. Serum starved RASMCs were treated with 10% FBS and 5 
μM Sen A for 30 min and subject to confocal microscopy analysis. Typical confocal 




Figure 3.18. The effect of CDK8 inhibitor Senexin A on FBS-induced AKT and CDK8 
association. Serum starved RASMCs were treated with 10% FBS and 5 μM Sen A for 30 
min then subjected to immunoprecipitation with AKT antibody followed by Western blot 
analysis. The representative results are from 3 separate experiments. 
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CHAPTER 4 
CYCLIN-DEPENDENT KINASE 8-MEDIATED VASCULAR SMOOTH 
MUSCLE CELL DEDIFFERENTIATION CONTRIBUTES TO 
NEOINTIMAL FORMATION 
4.1 INTRODUCTION: 
Vascular disease remains to the leading cause of mortality in the United States 
and worldwide.1,2 Neointimal formation (NI) is a key event in atherosclerosis and several 
other vascular diseases. NI is caused by an abnormal increase in cell population within 
the innermost layer of the arterial wall, resulting in a plaque formation that will 
eventually occlude the vessel. The underlying causes of NI include SMC migration, 
proliferation, and dedifferentiation.68,83 The neointima consists mainly of SMCs, however 
myofibroblasts and fibroblasts have also been reported to contribute to the neointima.81 
The carotid ligation surgery performed in mice has historically been used as a model to 
study vascular disease.99 The neointimal SMCs that arise following carotid artery ligation 
are largely derived from dedifferentiated vascular SMCs.63–65,67–69,81 
Our previous studies indicate that CDK8 is a positive regulator in SMC 
dedifferentiation via AKT/GSK3β-mediated enhancement of c-MYC stabilization. Due to 
these results, we predicted that CDK8 might also play a role in vascular lesion formation. 
To investigate the role of CDK8 in vascular lesion formation, we performed 
carotid ligation surgery on mice and tested the effects of CDK8 inhibition in neointimal 
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formation by utilizing a specific inhibitor of CDK8, Senexin A.61 We hypothesized that 
CDK8 inhibition can reduce neointimal formation after carotid ligation surgery in mice. 
In this report, we demonstrate that CDK8 is a critical mediator of vascular SMC 
dedifferentiation and NI formation at least partly via its ability to facilitate activation of 
the AKT/GSK3β/c-MYC stabilization signaling axis in vascular SMCs. Therefore, 
targeting CDK8 may be a novel therapeutic approach for the treatment of occlusive 
vascular disease due to the abnormal growth of vascular SMCs. 
 
4.2 MATERIALS AND METHODS: 
Immunoprecipitation, Immunoblotting and Immunohistochemical Analyses: 
Immunoprecipitation, immunoblotting, and immunohistochemical staining were 
performed as we previously reported.83,85,100 For confocal microscopic analysis of CDK8 
and AKT expression and localization in vascular SMCs, RASMCs (P6-10) at 80% 
confluent state were serum starved overnight prior to the treatment with vehicle DMSO 
(0.2%, vol/vol) and 5 µM Senexin A (0.2% DMSO, vol/vol) in serum-free (SF) DMEM 
or full growth medium for 30 min. These cells were then washed with ice-cold PBS twice 
and fixed in 4% paraformaldehyde for 10 min at room temperature. After treatment with 
0.01% triton X 100 for 1 min, all cells were incubated with 1% BSA at room temperature 
for 1 h. Primary antibodies used were anti-AKT (Cat#: 2920, 1:200 dilution, Cell 
Signaling), anti-CDK8 (Cat#: SC1521, 1:500 dilution, Santa Cruz Biotechnology) and 
anti-AKT (Cat#: 2920, 1:200 dilution, Cell Signaling). Secondary antibodies used were 
Alexa Fluor 488 (Donkey anti-Rabbit IgG (H+L) highly cross-adsorbed secondary 
antibody, Cat#: A-21206, 1:500 dilution, Invitrogen) and Alexa Fluor 546 (Donkey anti-
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Mouse IgG (H+L) highly cross-adsorbed secondary antibody, Cat#: A-10036, 1:500 
dilution, Invitrogen). The images were obtained under the same exposure condition. The 
expression of CDK8 in tissue sections of human coronary arteries with atherosclerotic 
lesions was also determined by confocal microscopic analysis using the antibodies above 
mentioned. Fluorescent images were acquired using Zeiss LSM 510 META confocal 
scanning laser microscope. 
Carotid Ligation Model: 
Male C57BL/6J mice at age of 12 wks were used for complete carotid artery ligation as 
previously described.99 Briefly, the mice were anesthetized by intraperitoneal injection of 
a solution of xylazine (5 mg/kg body weight) and ketamine (80 mg/kg body weight). The 
left common carotid artery was dissected and ligated near the carotid bifurcation. At each 
experimental end point, these mice were anesthetized with intraperitoneal injection of 
pentobarbital sodium (50 mg/kg body weight) and euthanized by exsanguination. Blood 
in the vessel was washed out by 0.9% NaCl perfusion for 5 min. The right carotid artery 
was not ligated and served as an internal control for morphological measurement. 
However, sham operated carotid arteries which were subjected to the same procedure 
except for the ligation were used as the sham control for signaling dissection. This is 
because in this mouse model, the complete ligation hardly induces neointimal hyperplasia 
but does have impact on gene expression in the contralateral carotid artery.99,101 In an 
effort to establish the complete carotid artery ligation model, we performed several sets 
of experiments to characterize the complete ligation-induced inward remodeling in 
carotid arteries. Whole carotid arteries were harvested at the experimental end points. 
From the ligation point or carotid bifurcation (internal control), serial cross-sections (5-
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µm thick per section) were then cut in 5-mm length, resulting in 1000 sections per carotid 
artery. Fifty sections located at 100-µm intervals from the ligation site or the carotid 
bifurcation was sampled and numbered (100-µm × 50 = 5-mm) for each carotid artery. 
We found that 30%~40% of ligated carotid arteries developed neointimal hyperplasia. In 
addition, the intimal hyperplasia of the ligated carotid arteries (n=10) mainly occurred 
within 2-3 mm of the vessel distal to the ligation site, which was maximal closest to the 
ligation site, decreased in the thickness in the direction to the aortic arch, and disappeared 
within the proximal 2-3 mm of the vessel adjacent to the aortic arch as previously 
reported. 99Hence, the segments (~5-mm) from the ligation site or bifurcation to the 
proximal site of the vessel adjacent to the aortic arch of sham-operated and ligated carotid 
arteries (n=10) were excised and subject to Western blot analysis as previously 
described.100 The contralateral (internal control) and ligated carotid arteries in a length of 
1 mm from the ligation site or bifurcation to the aortic arch were subject to 
morphological measurements of neointima formation, lumen patency, and cellular marker 
expression. Briefly, after flushing out the blood, these arteries were fixed with 4% 
paraformaldehyde under physiological pressure of 100 mmHg (13.3 kPa) for 10 min. 
Whole left and right carotid arteries without the proximal ~2-mm of the vessel adjacent to 
the aortic arch were harvested and further fixed with 4% phosphate-buffered 
formaldehyde at 4°C for 24 h. The fixed arteries were embedded in paraffin or OCT for 
sectioning. All carotid arteries were sectioned (5-µm thick per section) from the distal 
end. We analyzed 5 sections located at 100-µm intervals from the ligation site or 
bifurcation to the aortic arch of each control and ligated carotid arteries with or with 
Senexin A treatment. These sections were subject to hematoxylin and eosin (H&E) or 
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immunofluorescence staining. Nuclei were counterstained with 4,6-diamidino-2-
phenylindole (DAPI). The primary antibody for CDK8 staining was anti-CDK8 (Cat#: 
22067-1-AP, 1:500 dilution, Proteintech). The images were obtained under the same 
exposure condition. Fluorescent images were acquired using Zeiss LSM 510 META 
confocal scanning laser microscope. 
Drug Treatment: 
Senexin A was delivered locally as follows: Senexin A (30 µM/L) or vehicle control 
DMSO (0.3%, vol/vol) in 100 µl 20% Pluronic F-127 gel (Cat: BCBH4538V, Sigma-
Aldrich) was delivered to the adventitia of ligated arteries immediately after ligation. 
Statistics: 
Data are shown as mean ± SEM. Differences between 2 groups were evaluated for 
statistical significance using the Student t test when the sample size was appropriate and 
the population was distributed normally. When differences among > 3 groups were 
evaluated, results were compared by one-way ANOVA with Bonferroni test for multiple 
comparisons. Differences were considered significant at p < 0.05. 
 
4.3 RESULTS: 
A Mediator Role of CDK8 in Vascular SMC Dedifferentiation and NI formation in vivo: 
Our in vitro results encouraged us to examine the pathological relevance of the 
CDK8 signaling in vivo. Using a mouse model of NI formation in the carotid artery 
induced by complete ligation in which the majority (~80%) of NI cells is derived from 
mature vascular SMCs,81 we found that peri-vascular delivery of Sen A (30 µM/L) in 
20% Pluronic F-127 gel immediately after ligation procedure dramatically suppressed the 
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activation of AKT and the upregulation of c-MYC while reversing the downregulation of 
SMC markers such as αSMA, CNN1, and SM22α on 3 day after ligation (Figure 4.1), 
and significantly inhibited SMC accumulation in the NI (Figure 4.2) and NI formation 28 
day post-ligation (Figure 4.3). These findings reveal a potential role of the newly 
identified CDK8/AKT/GSK3β/c-MYC stabilization-signaling axis in mediating vascular 
SMC dedifferentiation and NI formation (Figure 4.4). 
 
4.4 DISCUSSION: 
Our previous studies uncover for the first time a novel signaling axis of CDK8-
AKT activation-GSK3β inhibition-c-MYC stabilization in mediating vascular SMC 
dedifferentiation, thus providing new insight into the pathogenesis of occlusive vascular 
disease associated with SMC dedifferentiation. Because of the firmly established concept 
that the abnormal growth and accumulation of dedifferentiated vascular SMCs largely 
contribute to vascular lesion formation,63–65,67–69,81 most of the therapeutic approaches for 
vascular diseases, in particular occlusive vascular disease, have focused on either direct 
or indirect inhibition of SMC proliferation in diseased vessels such as failing vein grafts 
.102,103 However, none of them are truly effective, thus the 10-year vein graft failure rates 
(~50%) have remained largely unchanged over the last two decades.102,103 The underlying 
reasons may be multifactorial, but a plausible interpretation is that the master regulators 
of vascular SMC dedifferentiation are still missing. In this regard, our serial findings 
indicate that CDK8 may be such a regulator. Firstly, we demonstrated that inactivation of 
CDK8 led to the suppression of vascular SMC dedifferentiation with typical synthetic 
phenotypes including increased proliferation, migration, and ECM secretion in vitro. 
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Secondly, we established that inactivation of CDK8 inhibited SMC accumulation in NI 
and NI formation of ligated carotid arteries, in which the majority (~80%) of NI cells is 
derived from mature vascular SMCs.81 Finally, we further confirmed the critical role of 
CDK8 in mediating the vascular SMC-dependent NI formation in other models of 
occlusive vascular remodeling, i.e., the transplantation of isologous jugular veins and the 
transplantation of decellularized aorta scaffolds in which we verified a major contribution 
of mature vascular SMCs to NI formation by genetic inducible fate mapping approach 104 
using myh11-CreERT2::Rosa26Floxed-Stop-eYFP mice (unpublished data). Given the 
availability of highly selective small molecule inhibitors of CDK8,105 these findings 
provide the rationale for the translational study of CDK8 inhibitors on the prevention 
and/or treatment of vascular lesion formation. 
 There are several issues requiring future studies. The mediator role of CDK8 in 
vascular SMC dedifferentiation leading to vascular lesion formation needs to be verified 
by genetic interrogations including mature vascular SMC specific CDK8 knockout 
approach in vivo. The potential off-target effects of CDK8 inhibitors also need to be 
evaluated via aforementioned genetic interrogations. Further investigation of these 
subjects will lead to a better understanding of CDK8-mediated vascular remodeling and 
dysfunction in pathological settings, therefore paving the way to develop novel 




Figure 4.1. Peri-vascular delivery of Senexin A is a mediator of AKT-c-MYC signaling 
and SMC dedifferentiation. Male adult C57BL/6J mice (n=20) were subjected to sham or 
complete carotid artery ligation with perivascular delivery of vehicle control or Sen A (30 
µM/L) after 3 days. Two pools of carotid arteries (n=10 for each pool of each group) 
were subjected to Western blot analysis as indicated (upper panel). Lower left panel is the 




Figure 4.2. Peri-vascular delivery of Senexin A significantly inhibited SMC accumulation 
in the NI. Male adult C57BL/6J mice (n=10) were subjected to sham or complete carotid 
artery ligation with perivascular delivery of vehicle control or Sen A (30 µM/L) for 28 
days. A. Characterization of complete ligation-induced neonitima formation in the carotid 
artery. B. αSMA expression in unligated and ligated carotid arteries of C57BL/6J mice 
(n=10) at 28 days after operation was analyzed by confocal microscopy. The 
representatives of αSMA staining are from 20 sections (n=4, 5 sections from each mouse) 





Figure 4.3. Peri-vascular delivery of Senexin A significantly inhibited NI. Male adult 
C57BL/6J mice (n=10) were subjected to sham or complete carotid artery ligation with 
perivascular delivery of vehicle control or Sen A (30 µM/L) for 28 days. Upper panel is 
the representative H&E staining and lower panel shows the quantified NI area using 




Figure 4.4. The potential role of CDK8/AKT/GSK3β/c-MYC stabilization signaling axis 
in mediating vascular SMC dedifferentiation and lesion formation. CDK8 is a critical 
mediator of SMC dedifferentiation at least partly by facilitating the AKT-mediated 





SUMMARY AND CONCLUSIONS 
 
Occlusive vascular disease, characterized by abnormal proliferation and 
accumulation of vascular SMCs in the vascular lesion, is one of the most common causes 
of morbidity and mortality in USA.62 Upon disease or injury mature and quiescent 
vascular SMCs undergo dedifferentiation which is characterized by a downregulation of 
SMC-specific contractile markers, and a concomitant with an increase in cell 
proliferation, migration, and ECM secretion, thereby leading to vascular lesion 
formation.63–69 However, the mechanisms regulating the process of SMC 
dedifferentiation remain unclear. The current study provides novel findings of a potential 
role of CDK8 in SMC dedifferentiation. We also characterized the molecular 
mechanisms through which CDK8 regulates SMC dedifferentiation, as well as the 
pathophysiological relevance of CDK8 in vivo. We hypothesized that CDK8 is a critical 
mediator in SMC dedifferentiation and vascular lesion formation. 
 For Aim 1,we demonstrated for the first time that CDK8 is normally expressed in 
endothelial cells and vascular SMCs, thus suggesting that CDK8 is expressed under 
normal physiological conditions in the vasculature. Moreover, CDK8 was shown to be 
upregulated in dedifferentiating vascular SMCs, suggesting that CDK8 may play a role in 
the pathological process of vascular disease. CDK8 inhibition was able to regulate all 
three events by promoting increased proliferation, migration and ECM secretion as well 
as promoting a synthetic phenotype.
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For Aim 2, we identified a novel signaling axis of CDK8-AKT activation-GSK3β 
inhibition-c-MYC stabilization in mediating SMC dedifferentiation. We uncovered that: 
activation of CDK8 promotes the activation AKT to suppress GSK3β-mediated 
phosphorylation of c-MYC at Thr58 for proteasomal degradation in RASMCs; CDK8 
activates AKT to suppress GSK3β-mediated c-MYC degradation thereby promoting 
RASMC dedifferentiation; and CDK8 kinase activity is critical for its association with 
AKT thereby activating AKT and AKT-driven signaling in vascular SMCs. 
 For Aim 3, we demonstrated that inactivation of CDK8 led to the suppression of 
vascular SMC dedifferentiation with typical synthetic phenotypes including increased 
proliferation, migration, and ECM secretion in vitro. Secondly, we established that 
inactivation of CDK8 inhibited SMC accumulation in NI. 
 In conclusion, our results demonstrate that CDK8 is a critical mediator of vascular 
SMC dedifferentiation at least partly by facilitating the AKT-mediated inhibition of 
GSK3β to stabilize c-MYC, thereby contributing to NI formation. Therefore, targeting 
CDK8 may be a novel therapeutic approach for the treatment of occlusive vascular 
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APPENDIX A. PATIENT MEDICAL HISTORY 
Table A.1. Tissue sections of arteries were prepared from autopsy organ specimens of 
humans with a cardiovascular disease history. 
 
Specimen # Sex Age Disease history Arterial occlusion 
14607 Male  97  Hypertension; Prostate 
cancer 
 
Left coronary artery (moderate 
atherosclerosis); Left circumflex 
coronary artery (mild to moderate 
atherosclerosis); Left anterior 
descending coronary artery (mild to 
moderate atherosclerosis) 
14608 Male  60 Septic shock; 
Disseminated 
intravascular coagulation 
Right coronary artery (mild 
atherosclerosis); Left anterior 
descending coronary artery (mild 
atherosclerosis)  
14609 Male  71 Coronary artery disease; 
Bypass graft 2015; 
Acute Myocardial 
Infarction (left ventricle 
interventricular septum) 
Left anterior ventricle circumflex 
coronary artery (sever atherosclerosis); 
Left anterior descending coronary 
artery (sever acute and chronic 
atherosclerosis); Left posterior ventricle 
posterior descending coronary artery 
(sever atherosclerosis) 
14612 Male  73 Chronic heart failure Aorta (mild atherosclerosis) 
14613 Female  71 Hypertension; 
Myocardial rupture 
Aorta (mild to moderate 
atherosclerosis) 
14610 Female  80 Hypertension; Asthma; 
Lung (squamous cell 
carcinoma) 
Right coronary artery (minimal to mild 
atherosclerosis) 
 
